&lt;p&gt;Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection – A Real-World Cohort Study&lt;/p&gt;

Luo, Yang; Zhang, Yue; Wang, Di; Shen, Di; Che, Yi-Qun

doi:10.2147/cmar.s254580

Cited by 6 publications

(1 citation statement)

References 35 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 52 Another retrospective analysis of HCC patients concludes that HCV elimination substantially improved OS in HCC patients with active HCV infection, and patients who did not receive antiviral therapy had a poorer prognosis. 53 Studies addressing the relationship between DAA-induced eradication and risk of HCC recurrence have produced contradictory data. 54 However, a recent review by Muzica et al 55 concludes that most recent and relevant articles suggest a reduced incidence rate of both de novo and recurrent HCC in patients with chronic hepatitis C, HCV-related cirrhosis, and HCV-related HCC, after achieving sustained viral response with direct-acting antiviral therapy.…”

Section: The Effect Of Carcinogenic Viruses On Survival/clinical Prac...mentioning

confidence: 99%

The Eradication of Carcinogenic Viruses in Established Solid Cancers

Elkoshi

2023

JIR

View full text Add to dashboard Cite

Carcinogenic viruses (oncoviruses) can initiate cancer, but their impact on established cancer varies. Some of these viruses prolong survival while others shorten it. This study classifies oncoviruses into two categories: viruses which induce a strong CD8+T cell reaction in non-cancerous tissues, and viruses which induce a weak CD8+ T cell reaction in non-cancerous tissues. The classification proves useful in predicting the effect of oncoviruses on the prognosis of solid cancers. Therefore, while eliminating carcinogenic viruses in healthy individuals (for example by immunization) may be important for cancer prevention, this study suggests that only viruses which induce a weak CD8+ T cell reaction should be eradicated in established solid tumors. The model correctly predicts the effect of oncoviruses on survival for six out of seven known oncoviruses, indicating that immune modulation by oncoviruses has a prominent effect on prognosis. It seems that CD8+ T cell response to oncoviruses observed in infected benign tissues is retained in infected tumors. Clinical significance: the effect of oncoviruses on solid cancer prognosis can be predicted with confidence based on immunological responses when clinical data are unavailable.

show abstract

Section: The Effect Of Carcinogenic Viruses On Survival/clinical Prac...mentioning

confidence: 99%

The Eradication of Carcinogenic Viruses in Established Solid Cancers

Elkoshi

2023

JIR

View full text Add to dashboard Cite

show abstract

Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival

Lockart

Hajarizadeh

Alavi

et al. 2021

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death in many parts of the world and is the fastest growing cause of cancer-related death in Australia. 1,2 Typically occurring in patients with underlying chronic liver disease, HCC is often detected at an advanced stage and has a high mortality-to-incidence ratio. [2][3][4] Chronic hepatitis C virus (HCV) infection is the most common cause of chronic liver disease and HCC in the majority of developed countries, including Australia. 5 Despite advances in HCC therapeutics in recent decades, HCC survival remains poor with a 5-year survival of 20%. 2

show abstract

Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib

Kuwano

Yada

Nagasawa

et al. 2022

Journal of Viral Hepatitis

View full text Add to dashboard Cite

The risk of hepatocellular carcinoma (HCC) occurrence following hepatitis C virus (HCV) eradication has been previously reported, but the impact of HCV eradication on advanced HCC patient survival remains unclear. Therefore, the present study aimed to evaluate the effect of HCV eradication on the survival outcome of patients with advanced HCC treated with sorafenib. One hundred and three HCV-related advanced HCC patients who were treated with sorafenib were enrolled in this study. Of these, 43 patients were administered antiviral therapy before sorafenib treatment (HCV eradication group), while 60 patients remained HCV-infected (HCV non-eradication group). We analysed the impact of HCV eradication on survival in advanced HCC treated with sorafenib. Median overall survival (OS) was significantly longer in the HCV eradication group than in the HCV non-eradication group (24.0 months vs. 14.1 months; p = 0.001). Although there was no significant difference in the albuminbilirubin (ALBI) score at the start of treatment between the HCV eradication group and the non-eradication group (p = 0.065), the ALBI score at 2 months after initiation of sorafenib treatment was significantly decreased in the HCV non-eradication group (p < 0.001), but not in the HCV eradication group (p = 0.121). Multivariate logistic analysis revealed HCV eradication (hazard ratio [HR], 0.5; p = 0.006) and ALBI score at the start of treatment (HR, 2.47; p = 0.002) as factors that may contribute to OS.HCV eradication may serve an important role in the survival outcome of advanced HCC patients treated with sorafenib.

show abstract

<p>Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection – A Real-World Cohort Study</p>

Cited by 6 publications

References 35 publications

The Eradication of Carcinogenic Viruses in Established Solid Cancers

The Eradication of Carcinogenic Viruses in Established Solid Cancers

Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival

Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib

Contact Info

Product

Resources

About